Antisense Reviews Could Move To CBER; FDA Defends Reorganization On Hill
Executive Summary
Antisense oligonucleotide products may be transferred from the Center for Drug Evaluation & Research to the Center for Biologics Evaluation & Research under the pending reorganization of review responsibilities